Last updated on December 2018

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol


Brief description of study

ORION-3 is a Phase II, open-label, non-randomized, active comparator extension trial to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).

Detailed Study Description

ORION-3, an extension of study MDCO-PCS-15-01 (ORION-1) [NCT02597127], is a Phase II, placebo-controlled, double-blind, randomized trial to evaluate the efficacy, safety, and tolerability of inclisiran (ALN-PCSSC) injection(s). All participants who completed ORION-1 (at least up to and including Day 210) and meet the study criteria will be enrolled into this study. ORION-3 is a long-term extension trial with an active comparator (evolocumab) in participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (diabetes, familial hypercholesterolemia) and elevated LDL-C, despite maximum tolerated dose of LDL-C lowering therapies.

Clinical Study Identifier: NCT03060577

Contact Investigators or Research Sites near you

Start Over

Global Health Science Center

Brampton Research Associates
Brampton, ON Canada
7.67miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.